Describing Patient With DME, Their Patient Journey and Disease Progression

Boehringer Ingelheim221,004 enrolled

Overview

This study aims to characterize patients with diabetic macular edema (DME), their progression, the treatment received and associate the functional and physiological outcomes related to the treatment.

Study Type

OBSERVATIONAL

Enrollment

221,004

Conditions

Diabetic Macular Edema

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: All patients ≥18 years, with a DME diagnosis in at least one eye, included in the Vestrum database identified during the study period (January 2015 to April 2023) Exclusion Criteria: Patients without the information of laterality will be excluded.

Locations (1)

CorEvitas HQ

Waltham, Massachusetts, United States

Outcomes

Primary Outcomes

Change in visual acuity

Time frame: From January 2015 to April 2023

Progression to DME in the fellow eye

Time frame: From January 2015 to April 2023

Initial treatment of DME

Time frame: From January 2015 to April 2023

Central retinal thickness (CRT)

Time frame: From January 2015 to April 2023

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.